Home > Publications database > Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Finnish Maternity Cohort. > print

001     276103
005     20240229154956.0
024 7 _ |a 10.1093/infdis/jiad171
|2 doi
024 7 _ |a pmid:37196097
|2 pmid
024 7 _ |a 0022-1899
|2 ISSN
024 7 _ |a 1537-6613
|2 ISSN
024 7 _ |a altmetric:148520129
|2 altmetric
037 _ _ |a DKFZ-2023-01003
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Skarga, Elizaveta
|0 P:(DE-He78)030207384715725dd6db597aa5c7311b
|b 0
|e First author
|u dkfz
245 _ _ |a Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Finnish Maternity Cohort.
260 _ _ |a Oxford [u.a.]
|c 2023
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1701334286_1987
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C020#LA:C020# / 2023 Nov 28;228(11):1621-1629
520 _ _ |a Sexually transmitted infections, specifically Chlamydia trachomatis (CT), may be associated with epithelial ovarian cancer (EOC) risk. The association between CT and EOC subtypes is unclear. Our aim was to investigate whether history of CT and other infections (M. genitalium (MG), herpes simplex virus type 2, and human papillomaviruses) are associated with EOC risk by histotype.We measured antibodies (Ab) to CT, MG, HSV2, and HPV-16 and 18 in serum samples in a nested case-control study in the Finnish Maternity Cohort (n= 484 cases 1:1 matched to controls). Logistic Regression was used to calculate relative risks (RRs) and 95% confidence intervals [CIs] in seropositive vs. seronegative individuals in all cases, as well as serous (n=249), clear cell and endometrioid (n=91), and mucinous (n=142) EOC.CT-seropositivity was not associated with EOC risk (e.g., CT pGP3-Ab RR=0.92 [0.72- 1.19]), regardless of disease subtype. We observed a positive association between MG-seropositivity and mucinous EOC (RR=1.66 [1.09-2.54]; p-het_histotype≤0.001), but not other subtypes. No associations were observed with seropositivity to multiple STIs.CT infection was not associated with EOC risk, with associations observed only for MG and mucinous EOC. Mechanisms linking MG to mucinous EOC remain to be elucidated.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Chlamydia Trachomatis
|2 Other
650 _ 7 |a Ovarian Cancer
|2 Other
650 _ 7 |a Risk
|2 Other
650 _ 7 |a Serology
|2 Other
650 _ 7 |a Sexually Transmitted Infections
|2 Other
700 1 _ |a Surcel, Heljä-Marja
|b 1
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 2
|u dkfz
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 3
|u dkfz
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1093/infdis/jiad171
|g p. jiad171
|0 PERI:(DE-600)1473843-0
|n 11
|p 1621-1629
|t The journal of infectious diseases
|v 228
|y 2023
|x 0022-1899
909 C O |p VDB
|o oai:inrepo02.dkfz.de:276103
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)030207384715725dd6db597aa5c7311b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-25
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J INFECT DIS : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J INFECT DIS : 2022
|d 2023-10-21
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Infektionen und Krebs-Epidemiologie
|x 1
920 0 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21